HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α ( HIF-2α ), exhibits an IC 50 of 0.4 µM and a K D of 1.1 µM. Anticancer agent In Vitro HIF-2α-IN-3 (Compound 1) inhibit HIF-2α-ARNT (also known as HIF-β) heterodimerization by binding an internal cavity of the HIF-2α PAS-B domain. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 0.4 µM (HIF-2α), KD: 1.1 µM (HIF-2α)